Skip to main content
SpringerLink
Log in

Oxidized low-density lipoprotein biomarkers in atherosclerosis

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The concept that the oxidation of lipoproteins is central in the pathogenesis of atherosclerosis was first reported over 25 years ago, initially by in vitro studies and subsequently through experimental models of atherosclerosis. The innate immune system plays a key role in atherogenesis as manifested by its atherosclerosis-modulating properties, the immunogenicity of oxidized low-density lipoprotein (LDL), and the presence of oxidized LDL autoantibodies in plasma and lesions of humans. In the past 10 years it has been possible to generate monoclonal antibodies to oxidized LDL to directly measure oxidized LDL in plasma. This has led to a rapidly accelerating pace of new reports on the relationship of circulating oxidized LDL and various cardiovascular pathologic processes, which are the focus of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tsimikas S, Glass C, Steinberg D, Witztum JL: Lipoproteins, lipoprotein oxidation and atherogenesis. In Molecular Basis of Cardiovascular Disease. A companion to Braunwald’s Heart Disease. Edited by Chien KR. Philadelphia: WB Saunders; 2004:385–413.

    Google Scholar 

  2. Navab M, Ananthramaiah GM, Reddy ST, et al.: Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993–1007.

    Article  PubMed  CAS  Google Scholar 

  3. Tsimikas S, Witztum JL: Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001, 103:1930–1932.

    PubMed  CAS  Google Scholar 

  4. Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868–874.

    Article  PubMed  CAS  Google Scholar 

  5. Palinski W, Napoli C: The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002, 16:1348–1360.

    Article  PubMed  CAS  Google Scholar 

  6. Tsimikas S, Palinski W, Halpern SE, et al.: Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999, 6:41–53.

    Article  PubMed  CAS  Google Scholar 

  7. Torzewski M, Shaw PX, Han KR, et al.: Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 2004, 24:2307–2312.

    Article  PubMed  CAS  Google Scholar 

  8. Ehara S, Ueda M, Naruko T, et al.: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103:1955–1960.

    PubMed  CAS  Google Scholar 

  9. Nishi K, Itabe H, Uno M, et al.: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002, 22:1649–1654.

    Article  PubMed  CAS  Google Scholar 

  10. Tsimikas S, Shortal BP, Witztum JL, Palinski W: In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000, 20:689–697.

    PubMed  CAS  Google Scholar 

  11. Tsimikas S, Palinski W, Witztum JL: Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:95–100.

    PubMed  CAS  Google Scholar 

  12. Aikawa M, Sugiyama S, Hill CC, et al.: Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002, 106:1390–1396.

    Article  PubMed  CAS  Google Scholar 

  13. Crisby M, Nordin-Fredriksson G, Shah PK, et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926–933.

    PubMed  CAS  Google Scholar 

  14. Cyrus T, Witztum JL, Rader DJ, et al.: Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999, 103:1597–1604.

    PubMed  CAS  Google Scholar 

  15. Hazen SL: Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 2004, 24:1143–1146.

    Article  PubMed  CAS  Google Scholar 

  16. Tsimikas S, Witztum JL, Miller ER, et al.: High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004, 110:1406–1412.

    Article  PubMed  CAS  Google Scholar 

  17. Tsimikas S, Brilakis ES, Miller ER, et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46–57.

    Article  PubMed  CAS  Google Scholar 

  18. Itabe H, Takeshima E, Iwasaki H, et al.: A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994, 269:15274–15279.

    PubMed  CAS  Google Scholar 

  19. Holvoet P, Perez G, Zhao Z, et al.: Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995, 95:2611–2619.

    PubMed  CAS  Google Scholar 

  20. Palinski W, Hörkkö S, Miller E, et al.: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996, 98:800–814.

    Article  PubMed  CAS  Google Scholar 

  21. Hörkkö S, Bird DA, Miller E, et al.: Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999, 103:117–128.

    PubMed  Google Scholar 

  22. Tsimikas S, Bergmark C, Beyer RW, et al.: Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003, 41:360–370.

    Article  PubMed  CAS  Google Scholar 

  23. Tsimikas S, Lau HK, Han KR, et al.: Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004, 109:3164–3170.

    Article  PubMed  CAS  Google Scholar 

  24. Itabe H, Yamamoto H, Imanaka T, et al.: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996, 37:45–53.

    PubMed  CAS  Google Scholar 

  25. Holvoet P, Harris TB, Tracy RP, et al.: Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: Findings from the health, aging, and body composition study. Arterioscler Thromb Vasc Biol 2003, 23:1444–1448.

    Article  PubMed  CAS  Google Scholar 

  26. Sigurdardottir V, Fagerberg B: Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002, 252:440–447.

    Article  PubMed  CAS  Google Scholar 

  27. Hulthe J, Fagerberg B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002, 22:1162–1167.

    Article  PubMed  CAS  Google Scholar 

  28. Liu ML, Ylitalo K, Salonen R, et al.: Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol 2004, 24:1492–1497.

    Article  PubMed  CAS  Google Scholar 

  29. Shoenfeld Y, Wu R, Dearing LD, Matsuura E: Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004, 110:2552–2558.

    Article  PubMed  Google Scholar 

  30. Virella G, Lopes-Virella MF: Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol 2003, 10:499.

    Article  PubMed  CAS  Google Scholar 

  31. Wu R, de Faire U, Lemne C, et al.: Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 1999, 33:53–59.

    PubMed  CAS  Google Scholar 

  32. Tanaga K, Bujo H, Inoue M, et al.: Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 2002, 22:662–666.

    Article  PubMed  CAS  Google Scholar 

  33. Zhang B, Bai H, Liu R, et al.: Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men. Metabolism 2004, 53:423–429.

    Article  PubMed  CAS  Google Scholar 

  34. Jarvisalo MJ, Lehtimaki T, Raitakari OT: Determinants of arterial nitrate-mediated dilatation in children: role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness. Circulation 2004, 109:2885–2889.

    Article  PubMed  CAS  Google Scholar 

  35. Penny WF, Ben Yehuda O, Kuroe K, et al.: Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 2001, 37:766–774.

    Article  PubMed  CAS  Google Scholar 

  36. Matsumoto T, Takashima H, Ohira N, et al.: Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol 2004, 44:451–457.

    Article  PubMed  CAS  Google Scholar 

  37. Kugiyama K, Sugiyama S, Soejima H, et al.: Increase in plasma levels of oxidized low-density lipoproteins in patients with coronary spastic angina. Atherosclerosis 2001, 154:463–467.

    Article  PubMed  CAS  Google Scholar 

  38. Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76–82.

    PubMed  CAS  Google Scholar 

  39. Mellwig KP, Baller D, Gleichmann U, et al.: Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998, 139:173–178.

    Article  PubMed  CAS  Google Scholar 

  40. Toshima S, Hasegawa A, Kurabayashi M, et al.: Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000, 20:2243–2247.

    PubMed  CAS  Google Scholar 

  41. Holvoet P, Mertens A, Verhamme P, et al.: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21:844–848.

    PubMed  CAS  Google Scholar 

  42. Edelstein C, Pfaffinger D, Hinman J, et al.: Lysine-phosphatidylcholine adducts in Kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003, 278:51841–52847.

    Article  CAS  Google Scholar 

  43. Holvoet P, Collen D, van de Werf F: Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999, 281:1718–1721.

    Article  PubMed  CAS  Google Scholar 

  44. Silaste ML, Rantala M, Alfthan G, et al.: Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol 2004, 24:498–503.

    Article  PubMed  CAS  Google Scholar 

  45. Diepeveen SH, Verhoeven GW, Van Der PJ, et al.: Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med 2005, 257:438–445.

    Article  PubMed  CAS  Google Scholar 

  46. Shimada K, Mokuno H, Matsunaga E, et al.: Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004, 174:343–347.

    PubMed  CAS  Google Scholar 

  47. Wallenfeldt K, Fagerberg B, Wikstrand J: Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med 2004, 256:413–420.

    Article  PubMed  CAS  Google Scholar 

  48. Meisinger C, Baumert J, Khuseyinova N, et al.: Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005, 112:651–657.

    Article  PubMed  CAS  Google Scholar 

  49. Hulthe J, Bokemark L, Fagerberg B: Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 2001, 21:101–107.

    PubMed  CAS  Google Scholar 

  50. Karvonen J, Paivansalo M, Kesaniemi YA, Hörkkö S: Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003, 108:2107–2112.

    Article  PubMed  CAS  Google Scholar 

  51. Binder CJ, Shaw PX, Chang MK, et al.: The role of natural antibodies in atherogenesis. J Lipid Res 2005, In press.

  52. Mustafa A, Nityanand S, Berglund L, et al.: Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000, 102:2576–2581.

    PubMed  CAS  Google Scholar 

  53. Lopes-Virella MF, Virella G, Orchard TJ, et al.: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999, 90:165–172.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular Medicine Program, University of California San Diego, 9350 Campus Point Drive, Cardiology Suite 2B, 92037-0975, La Jolla, CA, USA

    Sotirios Tsimikas MD

Authors
  1. Sotirios Tsimikas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sotirios Tsimikas MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsimikas, S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 8, 55–61 (2006). https://doi.org/10.1007/s11883-006-0065-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-006-0065-1

Keywords

Search

Navigation